LTR228 [LTR 228-TG, derivative of WIL-2NS (ATCC CRL-8155)] (ATCC
LTR228 [LTR 228-TG, derivative of WIL-2NS (ATCC CRL-8155)] (ATCC
规格:
货期:
编号:TS211605
品牌:Testobio
| 产品名称： | LTR228 LTR 228-TG, derivative of WIL-2NS (ATCC CRL-8155) (ATCC® HB-8502™) |
|---|---|
| 商品货号： | TS211605 |
| Organism： | Homo sapiens, human |
| Tissue： | spleen |
| Cell Type： | B lymphoblast; Epstein-Barr virus (EBV) transformed |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 xa0Cells contain Herpesvirus
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | hereditary spherocytosis |
| Age： | 5 years |
| Gender： | male |
| Ethnicity： | Caucasian |
| Applications： | The cells are resistant to 6-thioguanine and can be used in fusions with human B lymphocytes to produce human hybridomas. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype： | modal number = 48; Y present |
| Clinical Data： | male Caucasian 5 years |
| Genes Expressed： | immunoglobulin; monoclonal antibody (small amounts) |
| Cellular Products： | immunoglobulin; monoclonal antibody (small amounts) |
| Comments： | The cells are resistant to 6-thioguanine and can be used in fusions with human B lymphocytes to produce human hybridomas. The cells have a high cloning efficiency in soft agar and by limiting dilution. |
| Complete Growth Medium： | Iscoves modified Dulbeccos medium with 0.03% L-glutamine and 0.02 mM 6-thioguanine, 90%; fetal bovine serum, 10%
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | fetal bovine serum, 95%; DMSO, 5% |
| STR Profile： | Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11 D16S539: 11,12 D5S818: 12,13 D7S820: 9,12 THO1: 8,9.3 TPOX: 8,11 vWA: 17,20 |
| Isotype： | IgM; kappa light chain |
| Population Doubling Time： | 16 hrs |
| Name of Depositor： | Cetus Corp. |
| Deposited As： | Homo sapiens |
| U.S. Patent Number： | |
| References： | Raubitschek AR, et al. Human lymphoblastoid cell line and hybridomas derived therefrom. US Patent 4,624,921 dated Nov 25 1986 |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
LTR228 [LTR 228-TG, derivative of WIL-2NS (ATCC CRL-8155)] (ATCC
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | LTR228 LTR 228-TG, derivative of WIL-2NS (ATCC CRL-8155) (ATCC® HB-8502™) |
|---|---|
| 商品货号： | TS211605 |
| Organism： | Homo sapiens, human |
| Tissue： | spleen |
| Cell Type： | B lymphoblast; Epstein-Barr virus (EBV) transformed |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 xa0Cells contain Herpesvirus
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | hereditary spherocytosis |
| Age： | 5 years |
| Gender： | male |
| Ethnicity： | Caucasian |
| Applications： | The cells are resistant to 6-thioguanine and can be used in fusions with human B lymphocytes to produce human hybridomas. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype： | modal number = 48; Y present |
| Clinical Data： | male Caucasian 5 years |
| Genes Expressed： | immunoglobulin; monoclonal antibody (small amounts) |
| Cellular Products： | immunoglobulin; monoclonal antibody (small amounts) |
| Comments： | The cells are resistant to 6-thioguanine and can be used in fusions with human B lymphocytes to produce human hybridomas. The cells have a high cloning efficiency in soft agar and by limiting dilution. |
| Complete Growth Medium： | Iscoves modified Dulbeccos medium with 0.03% L-glutamine and 0.02 mM 6-thioguanine, 90%; fetal bovine serum, 10%
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | fetal bovine serum, 95%; DMSO, 5% |
| STR Profile： | Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11 D16S539: 11,12 D5S818: 12,13 D7S820: 9,12 THO1: 8,9.3 TPOX: 8,11 vWA: 17,20 |
| Isotype： | IgM; kappa light chain |
| Population Doubling Time： | 16 hrs |
| Name of Depositor： | Cetus Corp. |
| Deposited As： | Homo sapiens |
| U.S. Patent Number： | |
| References： | Raubitschek AR, et al. Human lymphoblastoid cell line and hybridomas derived therefrom. US Patent 4,624,921 dated Nov 25 1986 |
